Conjunctival goblet cells density and preservative‐free tafluprost therapy for glaucoma: an in vivo confocal microscopy and impression cytology study

TLDR: To evaluate the density of conjunctival goblet cells in glaucomatous patients treated with preservative‐free (PF) tafluprost, using laser scanning confocal microscopy (LSCM) and impression cytology (IC).

Abstract: . Purpose: To evaluate the density of conjunctival goblet cells (GCs) in glaucomatous patients treated with preservative-free (PF) tafluprost, using laser scanning confocal microscopy (LSCM) and impression cytology (IC). Methods:  Thirty glaucomatous patients (30 eyes) naive for therapy and thirty healthy subjects (30 eyes) were enrolled. Conjunctiva was examined by means of Heidelberg Retina Tomography/Rostock cornea module. Afterwards, the specimens for IC were obtained. Patients were randomized to PF-tafluprost (Group 1) or preserved latanoprost (Group 2) and controls to the vehicle of latanoprost (Group 3) or physiological buffered saline solution (Group 4). Both LSCM and IC were performed at baseline, and after the 1st and 6th months of therapy, GC density (GCD) (cells/mm2) was the main outcome measurement. Results:  Baseline. Mean GCD was 240.69 ± 25.43 and 232.65 ± 23.52, for LSCM, and 162.10 ± 23.44 and 164.71 ± 21.03 for IC in Group 1 and 2, respectively. GC density values were not significantly different in Group 3 and 4 (p > 0.05%). Month one. Mean GCD increased to 284.16 ± 43.88 and 230.62 ± 48.32 in Group 1 (p   0.05) whereas it decreased in Group 2 (p   0.05). Conclusions:  Treatment with PF tafluprost was associated with an increase in conjunctival GCD in glaucomatous eyes naive for therapy. Further studies are mandatory to verify this finding because its validation may have important consequences in the medical management of glaucoma.